A study on breast cancer CTCs conducted by Aktas et al. was recently able to identify AKT2 expression as a marker of epithelial-mesenchymal-transition (EMT) in more than 60% of CTC positive samples analyzed [63]. The gene discussed is AKT2; the disease is breast carcinoma.